Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada

被引：47

作者：

Blackhouse G. ^{[1
,2
]}

Gaebel K. ^{[1
,3
]}

Xie F. ^{[1
,2
,3
]}

Campbell K. ^{[1
,2
]}

Assasi N. ^{[1
,2
]}

Tarride J. ^{[1
,2
,3
]}

O'Reilly D. ^{[1
,2
,3
]}

Chalk C. ^{[4
]}

Levine M. ^{[2
,3
]}

Goeree R. ^{[1
,2
,3
]}

机构：

[1] PATH Research Institute, McMaster University, Hamilton, ON

[2] Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON

[3] Centre for Evaluation of Medicines, St. Joseph's Healthcare, Hamilton, ON

[4] Department of Neurology and Neurosurgery, McGill University, Montréal, QC

来源：

Cost Effectiveness and Resource Allocation | / 8卷 / 1期

关键词：

Corticosteroid Treatment; Quality Adjust Life Year; Probabilistic Sensitivity Analysis; Chronic Inflammatory Demyelinating Polyneuropathy; IVIG Treatment;

D O I：

10.1186/1478-7547-8-14

中图分类号：

学科分类号：

摘要：

Objectives: Intravenous immunoglobulin (IVIG) has demonstrated improvement in chronic inflammatory demyelinating polyneuropathy (CIDP) patients in placebo controlled trials. However, IVIG is also much more expensive than alternative treatments such as corticosteroids. The objective of the paper is to evaluate, from a Canadian perspective, the cost-effectiveness of IVIG compared to corticosteroid treatment of CIDP.Methods: A markov model was used to evaluate the costs and QALYs for IVIG and corticosteroids over 5 years of treatment for CIDP. Patients initially responding to IVIG could remain a responder or relapse every 12 week model cycle. Non-responding IVIG patients were assumed to be switched to corticosteroids. Patients on corticosteroids were at risk of a number of adverse events (fracture, diabetes, glaucoma, cataract, serious infection) in each cycle.Results: Over the 5 year time horizon, the model estimated the incremental costs and QALYs of IVIG treatment compared to corticosteroid treatment to be $124,065 and 0.177 respectively. The incremental cost per QALY gained of IVIG was estimated to be $687,287. The cost per QALY of IVIG was sensitive to the assumptions regarding frequency and dosing of maintenance IVIG.Conclusions: Based on common willingness to pay thresholds, IVIG would not be perceived as a cost effective treatment for CIDP. © 2010 Blackhouse et al; licensee BioMed Central Ltd.

引用

共 41 条

[31]

O'Reilly D., Hopkins R.B., Blackhouse G., Clarke P., Hux J., Guan J., Development of an Ontario diabetes economic model (ODEM) and application to a multidisciplinary primary care diabetes management program, (2006)

[32]

Hopkins R.B., Tarride J.E., Bowen J., Blackhouse G., O'Reilly D., Campbell K., Et al., Cost-effectiveness of reducing wait times for cataract surgery in Ontario, Can J Ophthalmol, 43, pp. 213-217, (2008)

[33]

Jampel H.D., Glaucoma patients' assessment of their visual function and quality of life, Trans Am Ophthalmol Soc, 99, pp. 301-317, (2001)

[34]

Life tables, Canada, provinces and territories, 2000-2002, (2006)

[35]

FDA Grants Priority Review of Gamunex® as a Treatment for Neurological Disorder CIDP, (2008)

[36]

Gamunex: Immune Globulin Intravenous (Human),10%. Product Monograph, (2008)

[37]

Labour Market Information: Wages and Salaries, (2008)

[38]

e-Formulary. Ontario drug benefit formulary/comparative drug index: electronic version, (2007)

[39]

Notice to pharmacies: regulation changes made to the Ontario drug benefit act (ODBA) and the drug interchangeability and dispensing fee act (DIDFA), (2009)

[40]

Rates and Statistics, (2008)

← 1 2 3 4 5 →